decorational arrow GLP-1 | 2 min. read

Life's a balancing act - life, work, and type 2 diabetes

The continued search for balance

Health doesn't exist in a vacuum. This might sound obvious, but it's worth reflecting that health comes alongside everything else in your life. You’re constantly juggling many responsibilities from one moment to the next, striving to find the right balance between work, family, social commitments and everyday routines. Living with type 2 diabetes, is another thing to juggle, but it shouldn’t get in the way of living your life.

With type 2 diabetes, your body may not respond effectively to a naturally occurring hormone called Glucagon-like peptide 1 (GLP-1).  GLP-1 increases insulin levels when it's needed, thereby lowering blood sugar levels. GLP-1 can also reduce food consumption, body weight and increase satiety. Researchers are also looking into the role of GLP-1 in the risk of cardiovascular events, such as heart disease and stroke. 

It can be hard for someone with type 2 diabetes to be in tune with their body when it doesn’t respond as well as it should to GLP-1.  But, what if your body worked in partnership with you, leaving you free to focus on other things in life rather than type 2 diabetes?

The Perfect Partner

When your body works in partnership, managing type 2 diabetes can become one less thing to juggle. Whether you are living with type 2 diabetes or care for someone who is - speak to your doctor about treatment options.

[19:05] Sarah Hietkamp
  1. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011; 54 (1): 10-18.
  2. Shah, M et al. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014; 15(3):181-7
  3. Barkas F, Elisaf M, Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol. 2019 Apr;26(4):559-565.
  4. Bellastella G, Maiorino MI, Longo M, Scappaticcio L, Chiodini P, Esposito K, Giugliano D. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke. 2020 Feb;51(2):666-669.
  5. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375 (4): 311-22
  6. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375 (19): 1834-1844
  7. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394 (10193): 121-130.

Related articles